Bupropion in Parkinson’s disease

Neurology

Volumn 34, Issue 8, 1984, Pages 1092-1094

  Goetz, Christopher G ^a   Tanner, Caroline M ^a   Klawans, Harold L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; TRIHEXYPHENIDYL;

CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DEPRESSION; DRUG THERAPY; HUMAN; PARKINSON DISEASE; PATIENT; THERAPY;

ADULT; AGED; BUPROPION; FEMALE; HUMAN; MALE; MIDDLE AGE; PARKINSON DISEASE; PROPIOPHENONES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0021234760     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.34.8.1092     Document Type: Article

References (6)

1. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): Evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 1980;215:127-34.
2. Canning H, Goof D, Leach MJ, et al. The involvement of dopamine in the central actions of bupropion, a new antidepressant. Br J Pharmacol 1979;66:104P.
3. Ungerstedt U. Postsynaptic supersensitivity after 6-OH- dopamine induced degeneration. Acta Physiol Scand 1971;367:69-71.
4. Zung WWK. Reviews of placebo-controlled trials of bupropion. J Clin Psychiatry 1983;44:104-14.
5. Fabré LF, Brodie KH, Garver D, Zung WWK. A multicenter evaluation of bupropion vs placebo. J Clin Psychiatry 1983;44:88-94.
6. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Antidepressive treatment in Parkinson disease. Acta Neurol Scand 1980;62:210-9.